Zoetis Inc. $ZTS Shares Sold by Dnca Finance

Dnca Finance decreased its position in Zoetis Inc. (NYSE:ZTS) by 11.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 59,800 shares of the company’s stock after selling 8,000 shares during the period. Dnca Finance’s holdings in Zoetis were worth $9,326,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Norges Bank purchased a new position in shares of Zoetis in the 2nd quarter valued at about $809,491,000. Nuveen LLC acquired a new stake in Zoetis in the first quarter valued at approximately $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares in the last quarter. Polen Capital Management LLC raised its stake in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. Finally, Impax Asset Management Group plc lifted its position in shares of Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after buying an additional 922,589 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 1.4%

Shares of NYSE ZTS opened at $118.69 on Friday. The stock has a market cap of $52.31 billion, a PE ratio of 19.98, a P/E/G ratio of 2.46 and a beta of 0.97. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $181.85. The company has a 50-day moving average of $133.77 and a 200 day moving average of $147.67.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.7%. The ex-dividend date was Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Wednesday. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus decreased their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.